Zoetis Inc. with ticker code (ZTS) now have 15 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $248.00 and $198.64 suggesting an average analyst share price target price of $220.12. (at the time of writing). Given that the stocks previous close was at $187.33 this indicates there is a potential upside of 17.5%. The day 50 moving average is $180.66 and the 200 day MA is $179.24. The company has a market cap of 84.53B. The stock price is currently at: $186.59 USD
The potential market cap would be $99,331,647,658 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 36.66, revenue per share of $19.46 and a 14.41% return on assets.
Zoetis Inc. is an animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health technology. It commercializes products across eight core species: dogs, cats and horses and cattle, swine, poultry, fish and sheep and within product categories, such as vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. The Company operates through two segments: the United States and International. Within each of these operating segments, it offers a product portfolio for both companion animal and livestock customers. The Company market its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company’s products are sold in more than 100 countries.
